Abraxis BioScience Announces Dates for 2007 Year-End Financial Results and Investor Conference Call
LOS ANGELES--(Business Wire)--
Abraxis BioScience, Inc. (NASDAQ: ABII), an integrated, global
biopharmaceutical company, today announced it will release its 2007
fourth quarter and year-end financial results after the market closes
on Monday, March 31, 2008. The company also said that senior
management will host an investor conference call the next day,
Tuesday, April 1, 2008, at 8:30 a.m. PT/11:30 a.m. ET to review the
company's financial results.
The conference call will be available to interested parties
through a live audio webcast at www.abraxisbio.com and
www.earnings.com.
About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology
company dedicated to the discovery, development and delivery of
next-generation therapeutics and core technologies that offer patients
safer and more effective treatments for cancer and other critical
illnesses. The company's portfolio includes the world's first and only
protein-based nanoparticle chemotherapeutic compound (ABRAXANE(R)),
which is based on the company's proprietary tumor targeting technology
known as the nab(TM) platform. The first FDA approved product to use
this nab platform, ABRAXANE(R), was launched in 2005 for the treatment
of metastatic breast cancer. Abraxis trades on the Nasdaq Global
Market under the symbol ABII. For more information about the company
and its products, please visit www.abraxisbio.com.
Abraxis BioScience, Inc.
Daniel Saks
Vice President, Investor Relations and
Corporate Communications
310.405.7417
or
Pondel Wilkinson Inc.
Rob Whetstone
310.279.5963
Copyright Business Wire 2008
